Advertisement
UK Markets close in 4 hrs 38 mins

  • FTSE 100

    8,447.90
    +66.55 (+0.79%)
     

  • FTSE 250

    20,701.02
    +169.72 (+0.83%)
     

  • AIM

    788.50
    +4.80 (+0.61%)
     

  • GBP/EUR

    1.1626
    +0.0015 (+0.13%)
     

  • GBP/USD

    1.2532
    +0.0008 (+0.0614%)
     

  • BTC-GBP

    50,283.98
    +1,505.27 (+3.09%)
     

  • CMC Crypto 200

    1,305.15
    -52.86 (-3.89%)
     

  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     

  • DOW

    39,387.76
    +331.36 (+0.85%)
     

  • CRUDE OIL

    79.91
    +0.65 (+0.82%)
     

  • GOLD FUTURES

    2,384.20
    +43.90 (+1.88%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     

  • DAX

    18,804.58
    +117.98 (+0.63%)
     

  • CAC 40

    8,255.62
    +67.97 (+0.83%)
     
PROPERTY:

Homes with investment potential

These residential properties could bring in a good ROI

FDA approves expanded indication for AstraZeneca's blood thinner

Reuters - UK Focus

Sept 3 (Reuters) - AstraZeneca Plc (NYSE: AZN - news) said the U.S (Other OTC: UBGXF - news) . Food and Drug Administration had approved a new dose of its blood thinner, Brilinta, for patients with a history of heart attack beyond the first year.

The health regulator approved Brilinta tablets at a new 60 mg dose, the company said on Thursday. (http://bit.ly/1N65F0b) (Reporting By Samantha Kareen Nair in Bengaluru; Editing by Maju Samuel)